Study: Genentech CC 46372

Written By Patrick Smith

40-week weight loss study for people who are overweight or obesity without diabetes.

Are you living with overweight or obesity and do not have diabetes? 

If so, you may be eligible to participate in a clinical research study evaluating a GLP-1 medicine (RO7795068) and an amylin analog (petrelintide) for weight management. 

ABOUT THE STUDY

This is a Phase 2 study evaluating how RO7795068 and petrelintide affect body weight.  

WHO MAY QUALIFY? 

You may be eligible to participate if you meet all the following: 

  • Age 18 years or older

  • Body mass index (BMI) of 27 or higher (classified as overweight or obesity) 

  • Do not have diabetes

  • Have not used any GLP-1-based medication — including pills or injections (such as Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, or Foundayo) within the past 6 months

  • Have never had surgery for treatment of obesity 

INTERESTED IN LEARNING MORE? 

Click below to complete a short questionnaire to see if you may be eligible.
(JotForm link) 

Study Sponsor: Hoffmann-La Roche

ClinicalTrials.gov ID: NCT07589686 https://clinicaltrials.gov/study/NCT07589686

Patrick Smith
Next

Study: Abbvie M25-998